Published in Eur J Haematol on March 01, 2001
Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia (2009) 3.23
Mutations and prognosis in primary myelofibrosis. Leukemia (2013) 3.13
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia (2007) 2.49
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res (2006) 2.41
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia (2008) 2.35
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia (2013) 2.25
Acute megakaryocytic leukemia (M7) in children. Mayo Clin Proc (1989) 2.13
Measurement of the intensity of cell surface antigen expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol (1994) 2.13
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia (2013) 2.11
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol (2001) 2.10
Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med (1990) 2.05
Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia (2006) 1.95
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia (2011) 1.88
Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: a review. Am J Hematol (1998) 1.85
Long-term use of anagrelide in young patients with essential thrombocythemia. Blood (2001) 1.81
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia (2011) 1.79
Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia (2010) 1.79
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol (2005) 1.75
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood (2001) 1.74
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia (2010) 1.72
Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia (2013) 1.69
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia (2010) 1.64
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia (2010) 1.63
Imatinib for systemic mast-cell disease. Lancet (2003) 1.62
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia (2009) 1.61
Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol (1999) 1.60
Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood (1996) 1.53
Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methods. Blood Cells Mol Dis (1996) 1.51
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia (2006) 1.51
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Leukemia (2005) 1.51
SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia (2011) 1.48
SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia (2013) 1.48
A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions. Eur J Haematol (2010) 1.45
Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood (1994) 1.45
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia (2010) 1.44
WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia (2005) 1.44
Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia (2002) 1.42
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia (2007) 1.42
Development of hepatic veno-occlusive disease after Mylotarg infusion for relapsed acute myeloid leukemia. Bone Marrow Transplant (2001) 1.40
Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflamm Bowel Dis (1999) 1.36
Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood (2000) 1.36
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia (2011) 1.35
WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia (2010) 1.34
Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant (2001) 1.32
Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant (2001) 1.31
Pseudoporphyria: a clinical and biochemical study of 20 patients. Mayo Clin Proc (2001) 1.30
Reversible marked splenomegaly in pernicious anemia. Ann Intern Med (1993) 1.30
Outcome of recipients of bone marrow transplants who require intensive-care unit support. Mayo Clin Proc (1992) 1.29
Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia (2007) 1.27
A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia (2010) 1.27
Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia (2010) 1.26
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant (2004) 1.26
Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia. Leukemia (2013) 1.22
Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest (2001) 1.20
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia (2011) 1.18
Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. Leukemia (2003) 1.18
Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. Leukemia (2001) 1.17
Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia (2006) 1.16
'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res (2006) 1.15
Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation--case report and review of literature. Ann Hematol (2001) 1.15
Pernicious anemia revisited. Mayo Clin Proc (1994) 1.13
Variations in bone density among persons of African heritage. Osteoporos Int (2002) 1.09
Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia (2011) 1.08
Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. Ann Hematol (2002) 1.07
Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia (2007) 1.06
Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia (2013) 1.06
A bone marrow report of absent stainable iron is not diagnostic of iron deficiency. Ann Hematol (2001) 1.05
Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res (2007) 1.04
The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia (2009) 1.04
Cytogenetic and molecular detection of residual leukemic cells after allogeneic bone marrow transplantation in chronic granulocytic leukemia. Mayo Clin Proc (1992) 1.04
The complete evaluation of erythrocytosis: congenital and acquired. Leukemia (2009) 1.03
Anemia after orchiectomy. Am J Hematol (1998) 1.02
Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation. Br J Haematol (1998) 1.02
Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia (2012) 1.01
AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia (2013) 1.01
Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Leukemia (2006) 1.01
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia (2011) 1.00
IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia (2011) 0.98
A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia (2007) 0.98
Environmental chemical exposures and disturbances of heme synthesis. Environ Health Perspect (1997) 0.98
A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol (1999) 0.97
Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med (1995) 0.97
The 5q- syndrome: a single-institution study of 43 consecutive patients. Blood (1993) 0.97
Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion. Mayo Clin Proc (1995) 0.97
IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia. Leukemia (2010) 0.96
Myelodysplasia with fibrosis: a distinct entity? Leuk Res (2001) 0.96
Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant (2006) 0.96
Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. Bone Marrow Transplant (2002) 0.95
Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood (2001) 0.94
Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol (1998) 0.94
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia (2007) 0.94
Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant (2003) 0.93
Treatment of systemic mast-cell disease with cladribine. N Engl J Med (2001) 0.93
Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant (2006) 0.93
Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up? Leukemia (2011) 0.91
Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol (2001) 0.91
The neurologic complications of B-cell chronic lymphocytic leukemia. Neurology (1997) 0.90
Clonal hierarchy and allelic mutation segregation in a myelofibrosis patient with two distinct LNK mutations. Leukemia (2011) 0.90